AegirBio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was SEK 0.093 million compared to SEK 1.7 million a year ago. Net loss was SEK 49.12 million compared to SEK 44.95 million a year ago. Basic loss per share from continuing operations was SEK 2.04 compared to SEK 2.35 a year ago.